[EN] FUSED HETEROCYCLES AS 5-HT2A RECEPTOR AGONISTS [FR] HÉTÉROCYCLES FUSIONNÉS UTILISÉS EN TANT QU'AGONISTES DU RÉCEPTEUR 5-HT2A
摘要:
The disclosure provides compounds, e.g., compounds of Formula I, and their use in treating medical diseases or disorders, such as neurological disorders. Pharmaceutical compositions and methods of making various azaindole and benzisoxazole compounds are provided. The compounds are contemplated to be modulators of the 5-hydroxytryptamine 2A (5-HT2A) receptor.
The Selective Cross-Coupling of Secondary Alkyl Zinc Reagents to Five-Membered-Ring Heterocycles Using Pd-PEPPSI-IHept<sup>Cl</sup>
作者:Bruce Atwater、Nalin Chandrasoma、David Mitchell、Michael J. Rodriguez、Matthew Pompeo、Robert D. J. Froese、Michael G. Organ
DOI:10.1002/anie.201503941
日期:2015.8.10
leads to β‐hydride elimination. Whereas catalysts have been reported that provide decent selectivity for the expected (non‐rearranged) cross‐coupled product with aryl or heteroaryl oxidative‐addition partners, none have shown reliable selectivity with five‐membered‐ring heterocycles. In this report, a new, rationally designed catalyst, Pd‐PEPPSI‐IHeptCl, is demonstrated to be effective in selective
A method for producing a 3-halo-1,2-benzisothiazole represented by the general formula (2):
wherein R
1
is a hydrogen atom, an alkyl group having 1 to 4 carbon atoms, an alkoxy group having 1 to 4 carbon atoms, an alkoxycarbonyl group having 2 to 5 carbon atoms, a nitro group or a halogen atom, and X is a halogen atom, the method characterized by reacting a 1,2-benzisothiazol-3-one represented by the general formula (1):
wherein R
1
is the same group as the R
1
defined in the above general formula (2), with a thionyl halide in a polar solvent. The 3-halo-1,2-benzisothiazole obtainable according to the method of the present invention is suitably used as production raw materials and the like for a medicament and the like.
The present invention relates to novel substituted imidazo[1,2-b]pyridazine compounds of Formula (I) pharmaceutical compositions thereof, and the use such compounds as corticotropin releasing factor 1 (CRF1) receptor antagonists in the treatment of psychiatric disorders and neurological diseases.
Diversifying Amino Acids and Peptides via Deaminative Reductive Cross-Couplings Leveraging High-Throughput Experimentation
作者:J. Cameron Twitty、Yun Hong、Bria Garcia、Stephanie Tsang、Jennie Liao、Danielle M. Schultz、Jennifer Hanisak、Susan L. Zultanski、Amelie Dion、Dipannita Kalyani、Mary P. Watson
DOI:10.1021/jacs.2c11451
日期:2023.3.15
A deaminative reductive coupling of amino acid pyridinium salts with aryl bromides has been developed to enable efficient synthesis of noncanonical amino acids and diversification of peptides. This method transforms natural, commercially available lysine, ornithine, diaminobutanoic acid, and diaminopropanoic acid to aryl alanines and homologated derivatives with varying chain lengths. Attractive features
temperature, ynamides undergo a [5 + 2] annulation reaction with 1,2-benzisothiazoles to afford 1,4-benzothiazepines, whereas under heating conditions a desulfurizative annulation reaction proceeds well to access 3-aminoisoquinolines. These two protocols provide biologically important 1,4-benzothiazepines and 3-aminoisoquinolines with high efficiency with broad substrate scopes under mild reaction conditions